Analysis of clinical factors impacting on the effective time of endocrine therapy for patients with prostate cancer
10.3760/cma.j.issn.1673-4904.2014.08.001
- VernacularTitle:影响前列腺癌内分泌治疗有效时间的临床因素分析
- Author:
Jian KANG
;
Dapeng WU
;
Qiang LIU
;
Haibo SHEN
;
Zhengqin GU
;
Junhao LIANG
;
Jun QI
- Publication Type:Journal Article
- Keywords:
Prostatic neoplasms;
Recurrence;
Endocrine therapy;
Gleason score
- From:
Chinese Journal of Postgraduates of Medicine
2014;37(8):1-4
- CountryChina
- Language:Chinese
-
Abstract:
Objective To assess the clinical factors impacting on the effective time of endocrine therapy for patients with prostate cancer.Methods The chnical data of 432 patients with prostate cancer who accepted endocrine therapy were analyzed retrospectively.The endpoint of the study was failure of endocrine therapy which was defined as continuous elevation of prostate specific antigen (PSA) from nadir for 2 times and more than 0.2 μg/L.The clinical data such as age,clinical stage,lymph node metastasis,bone metastasis,Gleason score,initial PSA,and PSA nadir were collected and their rehtionship with the effective time of endocrine therapy were further assessed via COX regression model.Results Age of onset was 57-88(73.70 ± 7.28) years.Initial PSA was 10.30-588.10(27.15 ± 75.90) μ g/L.The effective time of endocrine therapy was 3-62 (27.01 ± 13.10) months.Univariate regression analysis showed that initial PSA,clinical stage,Gleason score,PSA nadir,lymph node metastasis,bone metastasis were correlated with the effective time of endocrine therapy (P ＜ 0.01).Multivariate regression analysis showed that only Gleason score was correlated with the effective time of endocrine therapy(P=0.001).Compared with patients with Gleason score equal to or less than 3+4,patients with Gleason score equal to or more than 4+3 showed 2.49 fold increased risk of therapy failure (OR =2.49,95％ CI 1.44-4.30).Conclusion Gleason score has close relationship with the effective time of endocrine therapy for patients with prostate cancer,Gleason score equal to or more than 4+3 is an indicator for poor response to endocrine therapy.
